Q1 EPS Forecast for Tenax Therapeutics Lowered by Analyst

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities research analysts at Roth Capital cut their Q1 2025 earnings estimates for Tenax Therapeutics in a report released on Wednesday, March 26th. Roth Capital analyst J. Aschoff now expects that the specialty pharmaceutical company will post earnings per share of ($0.19) for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $3.27 EPS.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.34.

Other analysts have also recently issued reports about the stock. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a research note on Monday, March 10th. Finally, StockNews.com started coverage on shares of Tenax Therapeutics in a report on Friday, March 21st. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tenax Therapeutics Price Performance

TENX opened at $6.49 on Friday. The firm has a market capitalization of $25.73 million, a PE ratio of -1.22 and a beta of 2.20. The business’s 50-day moving average is $6.43 and its two-hundred day moving average is $5.42. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89.

Hedge Funds Weigh In On Tenax Therapeutics

Several hedge funds have recently modified their holdings of the stock. Vestal Point Capital LP purchased a new stake in Tenax Therapeutics during the 3rd quarter worth approximately $288,000. Sphera Funds Management LTD. acquired a new stake in shares of Tenax Therapeutics during the third quarter worth $101,000. Two Sigma Investments LP purchased a new stake in shares of Tenax Therapeutics during the fourth quarter valued at $84,000. Millennium Management LLC acquired a new position in shares of Tenax Therapeutics in the 4th quarter valued at $166,000. Finally, Janus Henderson Group PLC purchased a new position in Tenax Therapeutics in the 4th quarter worth $1,026,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.